ZhiYi Biotechnology Snares 110 Million Yuan Series B

ZhiYi Biotechnology announced the completion of 110 million RMB in Series B financing, co-invested by SDIC Ventures and KIP Capital. This round of funds is mainly used for clinical research and new pipeline development of the company's innovative drugs. Previously, the company had completed a 50 million yuan A round of financing in August 2018, which was invested by Shenzhen Venture Capital.

Founded in 2013, ZhiYi Biotechnology is a domestic enterprise in the field of Live biotherapeutics (LBPs) and Next-generation probiotics. The company has an international level of research on the relationship between human pathogenic bacteria spectrum and disease, new functional strain screening and target determination, and live bacteria drug research and development platform, and has established a complete industrialization system, and its business covers live bacteria drugs , General food, health food, etc.

In November 2019, ZhiYi Biotechnology's SK08 Bacteroides fragilis (Bacteroides fragilis) was approved to enter the clinic. It is the first LBP in China to enter the clinic. It has a new strain, original innovation, and has great industry influence. The company has established a complete technical system in the spectrum of microorganisms and pathogenic bacteria, separation of new functional strains and target determination, development of new live bacteria drugs and active ingredient drugs, and has a complete industrialization platform from preclinical to NDA.

Since the completion of the A round of financing in 2018, ZhiYi Biotechnology has actively promoted SK08 to complete phase I clinical trials and is currently launching phase II clinical trials. ZhiYi Biotechnology CEO Dr. Wang Ye introduced: "There are many new drug varieties on the ZhiYi Biotechnology pipeline that are rapidly advancing, and it is expected that the second variety IND will be achieved next year. This is an innovative drug that is urgently needed in clinical practice."

Regarding the investment in ZhiYi Biotechnology, SDIC entrepreneurs stated: “The human micro-ecology is equivalent to the human body’s “second genome”, which contains important genetic information. There are up to 10 million genes encoded, and the number of genetic codes can reach the number of human genes 150. It is closely related to human health, especially the intestinal micro-ecology is an important maintainer of human development and health, directly and indirectly regulating multiple system functions. At present, the global market for drugs related to intestinal microbes is huge.